Additional file 16 of DNA methylation and lipid metabolism: an EWAS of 226 metabolic measures

Additional file 16: Table S12. Results of the investigation into associations between metabolic measures-related CpG sites and clinical outcomes. Listed are the CpG site-clinical outcome (previous myocardial infarction, prevalent type 2 diabetes, obesity and prevalent hypertension) results for both model 1: logistic regression model with clinical outcome as dependent variable and technically adjusted methylation value as independent variable, adjusted for the following covariates: age, sex, BMI, C-reactive protein levels, hemoglobin A1c levels (except for diabetes model), history of myocardial infarction (except for the myocardial infarction model), smoking status, current hypertension (except for the hypertension model), physical activity, white blood cell count and estimated proportions of white blood cell type; or model 2, which is additionally adjusted for intake of lipid-lowering drugs. P: p value of the association; OR: odds ratio for a 1 standard deviation increase in methylation; CI: confidence interval; FDR: false discovery rate p value based on the Benjamini–Hochberg method applied to each outcome and model separately; M1: model 1; M2: model 2. *Association investigated using the KORA F4 data in [15]; **Association investigated using the KORA F4 data in [25].

附加文件16：表S12。代谢指标相关CpG位点（CpG site）与临床结局的关联研究结果。本表格列出了两种模型下的CpG位点-临床结局（既往心肌梗死、现患2型糖尿病、肥胖及现患高血压）分析结果：模型1为以临床结局为因变量、经技术校正的甲基化值为自变量的逻辑回归模型，校正协变量包括年龄、性别、体质量指数（Body Mass Index, BMI）、C反应蛋白水平、糖化血红蛋白A1c水平（糖尿病模型除外）、心肌梗死病史（心肌梗死模型除外）、吸烟状态、当前高血压状态（高血压模型除外）、体力活动水平、白细胞计数及白细胞分类比例估计值；模型2则额外校正了调脂药物摄入情况。P值：关联检验的p值；OR值：甲基化水平每升高1个标准差对应的比值比；CI值：置信区间；FDR值：分别针对每个结局与模型采用Benjamini–Hochberg法计算得到的错误发现率p值；M1：模型1；M2：模型2。* 关联分析基于文献[15]中的KORA F4队列数据；** 关联分析基于文献[25]中的KORA F4队列数据。